Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy

基于生理学的药代动力学模型 药理学 氟康唑 药代动力学 CYP3A型 药品 化学 伊曲康唑 不利影响 治疗药物监测 医学 内科学 细胞色素P450 抗真菌 皮肤病科 新陈代谢
作者
Buyun Chen,Diansong Zhou,Hua Wei,Marmor Yotvat,Li Zhou,Jean Cheung,Nicole Sarvaria,R. Lai,Shringi Sharma,Karthick Vishwanathan,Joseph A. Ware
出处
期刊:British Journal of Clinical Pharmacology [Wiley]
卷期号:88 (8): 3716-3729 被引量:8
标识
DOI:10.1111/bcp.15278
摘要

Clinical drug interaction studies with itraconazole and rifampicin have demonstrated that acalabrutinib is a sensitive substrate of CYP3A. A physiologically based pharmacokinetic (PBPK) model was developed based on the data of these studies. One of the active CYP3A metabolites, ACP-5862, was identified but never studied in a drug interaction scenario. This study aims to evaluate both parent and metabolite exposure change with coadministration of moderate CYP3A inhibitors and its impact on safety and efficacy.In an open label, randomized, 2-period study, we investigated the effect of coadministration of fluconazole or isavuconazole on the pharmacokinetics of acalabrutinib. Bruton tyrosine kinase receptor occupancy and safety were compared between different treatments. Experimental data were compared to PBPK simulation results.Least square means of acalabrutinib maximum plasma concentration and area under the curve increased 1.37 (1.14-1.64) and 1.60 (1.45-1.77)-fold in the presence of isavuconazole and 1.48 (1.10-1.98) and 2.16 (1.94-2.40)-fold in the presence of fluconazole, respectively. For ACP-5862, these values are 0.72 (0.63-0.82) and 0.91 (0.86-0.97) fold for isavuconazole and 0.65 (0.49-0.87) and 0.95 (0.91-0.99) fold for fluconazole coadministration. The PBPK model was able to recover acalabrutinib and ACP-5862 PK profiles in the study. Bruton tyrosine kinase receptor occupancy change was minimal in the presence of isavuconazole. There were no deaths, serious adverse events (AEs), or subject discontinuation due to AEs in this study. Only mild (Grade 1) AEs were reported during the study, by 17% of the study population.Our results demonstrate the impact of fluconazole and isavuconazole on the pharmacokinetics of acalabrutinib and ACP-5862, and suggest that no dose adjustment is needed for concomitant administration with moderate CYP3A inhibitors. the current PBPK model can be used to propose dose adjustment for drug interactions via CYP3A.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sober完成签到,获得积分10
2秒前
电池高手发布了新的文献求助10
2秒前
动人的诗霜完成签到 ,获得积分10
2秒前
3秒前
7秒前
哈哈完成签到,获得积分10
10秒前
11秒前
善学以致用应助D_采纳,获得10
13秒前
风清扬应助社科狗采纳,获得50
13秒前
科研通AI5应助李天王采纳,获得20
14秒前
14秒前
kingking完成签到,获得积分10
16秒前
丘比特应助SSS水鱼采纳,获得10
16秒前
16秒前
16秒前
ll完成签到,获得积分10
17秒前
风味烤羊腿完成签到,获得积分0
18秒前
18秒前
baibai完成签到,获得积分10
19秒前
猪猪hero应助魏开铭采纳,获得10
20秒前
大模型应助一只奇怪的鸟采纳,获得10
20秒前
21秒前
lyh发布了新的文献求助10
21秒前
23秒前
李健应助科研通管家采纳,获得10
23秒前
23秒前
wanci应助科研通管家采纳,获得10
24秒前
852应助科研通管家采纳,获得10
24秒前
ll应助科研通管家采纳,获得10
24秒前
24秒前
24秒前
24秒前
24秒前
小麻花完成签到,获得积分10
24秒前
量子星尘发布了新的文献求助10
25秒前
humble完成签到 ,获得积分10
25秒前
木子木完成签到,获得积分10
26秒前
27秒前
Wind发布了新的文献求助10
27秒前
和谐的映梦完成签到,获得积分10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975516
求助须知:如何正确求助?哪些是违规求助? 3519930
关于积分的说明 11200130
捐赠科研通 3256278
什么是DOI,文献DOI怎么找? 1798183
邀请新用户注册赠送积分活动 877425
科研通“疑难数据库(出版商)”最低求助积分说明 806320